NCT06320717

AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma

A Retrospective/Prospective Study of an Artificial Intelligence Derived Histological Biomarker to Select Neoadjuvant Treatment for Patients With Borderline Resectable or Resectable Pancreatic Ductal Adenocarcinoma

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 100 (estimated)
• Sponsor: Roswell Park Cancer Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To collect samples and information from patients who will be undergoing standard of care neoadjuvant treatment with either FOLFIRINOX or Gemcitabine + Nab-paclitaxel. The information collected will be used to determine if there are any "biomarkers" in your blood or tumor tissue that, when compared to your response to the neoadjuvant treatment, could be used to choose the best treatment option for future patients with similar biomarkers.

Conditions

• Pancreatic Ductal Adenocarcinoma

Interventions

Type	Name	Description
OTHER	Blood sample	To determine if there are any biomarkers in the blood that could be used to choose best treatment plan for future patients

Timeline

• Start date: 2024-01-02
• Primary completion: 2026-07-02
• Completion: 2026-07-02
• First posted: 2024-03-20
• Last updated: 2025-04-25

Locations

2 sites across 1 country: United States